As we observed KRAS mutations to closely associate with wild-type GNAS IPMN lesions, we decided to use a broader cohort of PDAC cases, not uniquely limited to IPMN, to test whether this association is relevant in a more general context in pancreatic cancer. This evidence concerns the gene GNAS and familial pancreatic carcinoma.